Suzhou Medical College of Soochow University, 199 Renai Road, Suzhou, Jiangsu, 215123, China.
School of Nursing, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu, 210023, China.
BMC Cardiovasc Disord. 2024 Oct 26;24(1):592. doi: 10.1186/s12872-024-04232-z.
The effectiveness and adverse effects of coenzyme Q10 for heart failure remain unclear owing to small sample sizes and variations in the quality of existing studies in literature.
The databases of EMBASE, PubMed, Web of Science, CINAHL databases, Scopus, Cochrane Central Register of Controlled Trials, VIP, Wanfang, and CNKI were searched for randomized controlled trials on the coenzyme Q10-assisted treatment of heart failure. Relevant literature was retrieved, data were extracted, and the risk of bias of the included studies was evaluated by two investigators independently using the Review Manager 5.4 software and the STATA 15 software.
In total, 33 studies were included in this meta-analysis, which showed that all-cause mortality [RR = 0.64, 95% CI (0.48, 0.85), P = 0.002; GRADE: moderate quality], hospitalization for heart failure [RR = 0.50, 95% CI (0.37, 0.67), P < 0.00001; GRADE: moderate quality], New York Heart Association classification [MD = - 0.29, 95% CI (- 0.39, - 0.19), P < 0.00001; GRADE: low quality], and brain natriuretic peptide level [MD = - 91.97, 95% CI (- 103.11, - 80.83), P < 0.00001; GRADE: low quality] were lower in the coenzyme Q10 group than in the control group. Meanwhile, left ventricular ejection fraction [MD = 0.51, 95% CI (0.31, 0.71), P < 0.00001; GRADE: low quality] and 6-min walk test result [MD = 31.70, 95% CI (19.96, 43.43), P < 0.00001; GRADE: moderate quality] were better than those in the control group.
According to the existing evidence, coenzyme Q10 reduces all-cause mortality, hospitalization for heart failure, New York Heart Association classification, and brain natriuretic peptide level and improves left ventricular ejection fraction and 6-min walk test result in those with heart failure without major adverse effects.
This study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO, http://www.crd.york.ac.uk/prospero ), with the registration number CRD42023493184.
由于现有文献中研究样本量小且质量存在差异，辅酶 Q10 治疗心力衰竭的有效性和不良反应仍不清楚。
检索 EMBASE、PubMed、Web of Science、CINAHL 数据库、Scopus、Cochrane 对照试验中心注册数据库、维普、万方和中国知网，以评估辅酶 Q10 辅助治疗心力衰竭的随机对照试验。由两名研究者独立使用 Review Manager 5.4 软件和 STATA 15 软件检索相关文献、提取数据，并评估纳入研究的偏倚风险。
共有 33 项研究纳入本荟萃分析，结果显示全因死亡率[RR=0.64，95%CI（0.48，0.85），P=0.002；GRADE：中等质量]、心力衰竭住院率[RR=0.50，95%CI（0.37，0.67），P<0.00001；GRADE：中等质量]、纽约心脏协会分级[MD=-0.29，95%CI（-0.39，-0.19），P<0.00001；GRADE：低质量]和脑钠肽水平[MD=-91.97，95%CI（-103.11，-80.83），P<0.00001；GRADE：低质量]均低于对照组。同时，左心室射血分数[MD=0.51，95%CI（0.31，0.71），P<0.00001；GRADE：低质量]和 6 分钟步行试验结果[MD=31.70，95%CI（19.96，43.43），P<0.00001；GRADE：中等质量]优于对照组。
根据现有证据，辅酶 Q10 可降低心力衰竭患者的全因死亡率、心力衰竭住院率、纽约心脏协会分级和脑钠肽水平，改善左心室射血分数和 6 分钟步行试验结果，且无重大不良反应。
本研究方案已在国际前瞻性系统评价注册库（PROSPERO，http://www.crd.york.ac.uk/prospero）注册，注册号为 CRD42023493184。
